{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:50:19Z","timestamp":1761598219315},"reference-count":87,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to differences in clinical, laboratory, and disease parameters. Although generally considered incurable, prognosis for early and advanced stage disease has improved because of therapeutic advances, several of which have resulted from elucidation of the biologic and molecular basis of the disease. The choice of treatment for FL is highly dependent on patient and disease characteristics. Several tools are available for risk stratification, although limitations in their routine clinical use exist. For limited disease, treatment options include radiotherapy, rituximab monotherapy or combination regimens, and surveillance. Treatment of advanced disease is often determined by tumor burden, with surveillance or rituximab considered for low tumor burden and chemoimmunotherapy for high tumor burden disease. Treatment for relapsed or refractory disease is influenced by initial first-line therapy and the duration and quality of the response. At present, there is no consensus for treatment of patients with early or multiply-relapsed disease; however, numerous agents, combination regimens, and transplant options have demonstrated efficacy. While the number of therapies available to treat FL has increased together with an improved understanding of the underlying biologic basis of disease, the best approach to select the most appropriate treatment strategy for an individual patient at a particular time continues to be elucidated. This chapter considers prognostic factors and the evolving treatment landscape of FL, including recent and emerging therapies, as well as remaining unmet needs.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000444","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T21:02:18Z","timestamp":1591909338000},"page":"231-240","source":"Crossref","is-referenced-by-count":7,"title":["Advances in Treatment of Follicular Lymphoma"],"prefix":"10.1097","volume":"26","author":[{"given":"Stefano","family":"Luminari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[{"name":"Haematology Department, Concord Repatriation General Hospital, University of Sydney, Sydney, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Dental Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib2-20230924","article-title":"Who classification of tumors of hematopoietic and lymphoid tissues, revised 4th edition","year":"2017","journal-title":"IARC Libr"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group","volume":"84","year":"1994","journal-title":"Blood"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi","volume":"24","year":"2013","journal-title":"Ann Oncol"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinternmed.2007.125","article-title":"Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century","volume":"168","year":"2008","journal-title":"Arch Intern Med"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","year":"1986","journal-title":"J Clin Oncol"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center","volume":"13","year":"1995","journal-title":"J Clin Oncol"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","article-title":"Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-Tositumomab: long-term follow-up of phase III randomized study SWOG-S0016","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","year":"2004","journal-title":"Blood"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/bloodadvances.2019032136","article-title":"Impact of age on clinical risk scores in follicular lymphoma","volume":"3","year":"2019","journal-title":"Blood Adv"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"International Non-Hodgkin's Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"bib18-20230924","first-page":"783","article-title":"Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases","volume":"95","year":"2000","journal-title":"Intergruppo Italiano Linfomi. Blood"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","year":"1997","journal-title":"J Clin Oncol"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","year":"2014","journal-title":"Lancet Haematol"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V89.2.724","article-title":"Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting","volume":"89","year":"1997","journal-title":"Blood"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1200\/JCO.1995.13.5.1073","article-title":"Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma","volume":"13","year":"1995","journal-title":"J Clin Oncol"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","year":"2002","journal-title":"Blood"},{"key":"bib27-20230924","first-page":"530","article-title":"\u201c\u2018Minor\u2019\u201d BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases","volume":"9","year":"2007","journal-title":"J Mol Diagn"},{"issue":"5\u20136","key":"bib28-20230924","first-page":"605","article-title":"A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma","volume":"42","year":"2003","journal-title":"Acta Oncol"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","year":"2011","journal-title":"Radiother Oncol"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","year":"2014","journal-title":"Lancet Oncol"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","article-title":"Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/1097-0142(19930401)71:7<2342::AID-CNCR2820710728>3.0.CO;2-I","article-title":"Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study","volume":"71","year":"1993","journal-title":"Cancer"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF02990087","article-title":"A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma","volume":"11","year":"1994","journal-title":"Med Oncol"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ijrobp.2015.12.019","article-title":"Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: results of a multicenter study","volume":"94","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3109\/10428194.2014.990010","article-title":"Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?","volume":"56","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1756-8722-6-45","article-title":"Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?","volume":"6","year":"2013","journal-title":"J Hematol Oncol"},{"key":"bib37-20230924","first-page":"6701","article-title":"Radiotherapy for stage I\/II follicular lymphoma (FL): is it time for a re-appraisal?","volume":"34","year":"2014","journal-title":"Anticancer Res"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"e0131158","DOI":"10.1371\/journal.pone.0131158","article-title":"Radiotherapy compared to other strategies in the treatment of stage I\/II follicular lymphoma: a study of 404 patients with a median follow-up of 15 years","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.leukres.2015.05.009","article-title":"The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment","volume":"39","year":"2015","journal-title":"Leuk Res"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","article-title":"Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","year":"2014","journal-title":"Lancet Oncol"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: r","volume":"106","year":"2005","journal-title":"Blood"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","year":"2005","journal-title":"Blood"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an east German study group hematology and oncology study","volume":"25","year":"2007","journal-title":"J Clin Oncol"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus Lenalidomide in advanced untreated follicular lymphoma","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","year":"2011","journal-title":"Lancet"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography\u2013computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/annonc\/mdt562","article-title":"The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)","volume":"25","year":"2014","journal-title":"Ann Oncol"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","year":"1999","journal-title":"Blood"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib59-20230924","article-title":"Augment: a phase iii randomized study of lenalidomide plus rituximab (r2) vs rituximab\/placebo in patients with relapsed\/refractory indolent non-hodgkin lymphoma","year":"2018","journal-title":"Present Am Soc Hematol Annu Meet San Diego"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.12.006","article-title":"Positron-emission tomography\u2013based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma","volume":"126","year":"2020","journal-title":"Eur J Cancer"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/hon.2437_3","article-title":"Interim report from a phase 2 multicenter study of TAZEMETOSTAT, an EZH2 inhibitor, in patients with relapsed OR refractory b-cell non-HODGKIN lymphomas","volume":"35","year":"2017","journal-title":"Hematol Oncol"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1182\/blood.V128.22.3464.3464","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma- retrospective analysis of 2 randomized trials of the German low grade lymphoma study group","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German low grade lymphoma study group","volume":"24","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: a national LymphoCare study and Center for International Blood and Marrow Transplant Research Analysis","volume":"24","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hon.2553","article-title":"Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment","volume":"36","year":"2018","journal-title":"Hematol Oncol"},{"key":"bib66-20230924","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"bib67-20230924","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrc.2017.127","article-title":"From genetics to the clinic: a translational perspective on follicular lymphoma","volume":"18","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","year":"2013","journal-title":"Blood"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.14698","article-title":"A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma","volume":"178","year":"2017","journal-title":"Br J Haematol"},{"key":"bib71-20230924","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"bib72-20230924","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.12819","article-title":"A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"165","year":"2014","journal-title":"Br J Haematol"},{"key":"bib73-20230924","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2016.154377","article-title":"Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study","volume":"102","year":"2017","journal-title":"Haematologica"},{"issue":"15_supp","key":"bib74-20230924","first-page":"7519","article-title":"Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib76-20230924","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","year":"2018","journal-title":"J Immunother Cancer"},{"key":"bib77-20230924","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib78-20230924","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","year":"2014","journal-title":"Lancet Oncol"},{"key":"bib79-20230924","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"issue":"15_supp","key":"bib80-20230924","first-page":"7504","article-title":"Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed\/refractory non-Hodgkin lymphoma: Initial phase 1b\/2 results","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib81-20230924","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejps.2017.02.034","article-title":"A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas","volume":"103","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"bib83-20230924","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/hon.2438_144","article-title":"POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED\/REFRACTORY FL OR DLBCL: UPDATED RESULTS OF A PHASE 1B\/2 STUDY","volume":"35","year":"2017","journal-title":"Hematol Oncol"},{"key":"bib84-20230924","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood.V128.22.622.622","article-title":"Polatuzumab Vedotin combined with Obinutuzumab for patients with relapsed or refractory non-Hodgkin lymphoma: preliminary safety and clinical activity of a phase Ib\/II study","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib86-20230924","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2019-121460","article-title":"First-in-Human, Phase 1\/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody\u00ae-CD3\u00d7CD20) in B-Cell Non-Hodgkin Lymphomas","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib87-20230924","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/hon.58_2629","article-title":"Clinical activity of REGN1979, an anti-CD20 x anti-CD3 bispecific antibody (ab) in patients (pts) with (w\/) relapsed\/refractory (r\/r) b-cell non-HODGKIN lymphoma (b-NHL)","volume":"37","year":"2019","journal-title":"Hematol Oncol"},{"issue":"Supplement 1","key":"bib90-20230924","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-99-118344","article-title":"Mosunetuzumab, a Full-Length Bispecific CD20\/CD3 Antibody, Displays Clinical Activity in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib93-20230924","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","year":"2017","journal-title":"Mol Ther"},{"key":"bib95-20230924","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2019000151","article-title":"Tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion","volume":"3","year":"2019","journal-title":"Blood Adv"},{"key":"bib96-20230924","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib97-20230924","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","year":"2019","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:26:53Z","timestamp":1695533213000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000444","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}